Jaguar Animal Health (JAGX) to Release Earnings on Monday

Jaguar Animal Health (NASDAQ:JAGX) is expected to be releasing its Q4 2025 results after the market closes on Monday, April 6th. Analysts expect Jaguar Animal Health to post earnings of ($4.26) per share and revenue of $4.21 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, April 10, 2026 at 4:00 PM ET.

Jaguar Animal Health Stock Performance

Shares of NASDAQ JAGX opened at $0.40 on Friday. The firm’s 50-day moving average price is $0.57 and its 200-day moving average price is $1.20. Jaguar Animal Health has a 52-week low of $0.31 and a 52-week high of $15.48. The company has a market cap of $1.49 million, a PE ratio of -0.01 and a beta of 0.27. The company has a quick ratio of 0.52, a current ratio of 0.81 and a debt-to-equity ratio of 4.08.

Analyst Upgrades and Downgrades

Several brokerages recently commented on JAGX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Thursday, January 22nd. Wall Street Zen cut Jaguar Animal Health to a “strong sell” rating in a research report on Friday, January 23rd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $60.00.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.